By Alison Noon ( August 3, 2018, 6:31 PM EDT) -- Keryx Biopharmaceuticals Inc. has refused to accept a judge's decision that a proposed class action validly alleged that the company misled investors to believe it had mitigated supply chain risks before its stock tumbled due to a production delay of Auryxia, a treatment for symptoms of renal disease....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.